Non-Small-Cell Lung Cancer | Pharmacor | G7 | 2015
Last Updated 23 October 2015
Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-defined patient subpopulations—continue to evolve, driven by the approval of novel agents, often with associated biomarkers. Several underserved areas of high unmet need offer significant commercial opportunity for innovative agents. This report provides insight on how treatment options for NSCLC patients are likely to change over the next decade. It also provides analysis of the current and future earnings potential of drugs already in the market and of drugs anticipated to be approved for this indication.
Related Market Assessment Reports
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently…
Report
Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. In 2024, Imfinzi…
Report
Non-Small-Cell Lung Cancer – Current Treatment – Treatment Sequencing – Non-Small-Cell Lung Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
